<DOC>
	<DOC>NCT00657683</DOC>
	<brief_summary>The goals of the proposed study are to evaluate the safety, tolerability and immunogenicity of a GBS vaccine. Previous studies suggest that immune responses against GBS can protect humans from infection.</brief_summary>
	<brief_title>A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy females 18 through 40 years of age; have provided written informed consent after the nature of the study has been explained; are available for all visits scheduled for the study (i.e. are not planning to leave the area before the end of the study period); are in good health as determined by: medical history, physical assessment, clinical judgment of the investigator unwilling or unable to give written informed consent to participate in the study; pregnant (serum pregnancy test) unwilling to use acceptable birth control from screening and until at least 3 months after the final immunization nursing (breastfeeding) mothers</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>GBS</keyword>
	<keyword>GBS prevention</keyword>
</DOC>